tradingkey.logo

Neuropace Inc

NPCE
View Detailed Chart

10.320USD

+0.430+4.35%
Close 09/18, 16:00ETQuotes delayed by 15 min
341.02MMarket Cap
LossP/E TTM

Neuropace Inc

10.320

+0.430+4.35%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.35%

5 Days

+3.10%

1 Month

+22.57%

6 Months

-9.47%

Year to Date

-7.77%

1 Year

+51.32%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
46 / 207
Overall Ranking
143 / 4721
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Buy
Current Rating
16.857
Target Price
+70.45%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 75.54% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 79.91M.
Undervalued
The company’s latest PE is -12.43, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 29.13M shares, decreasing 3.88% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.37M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.28.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
Ticker SymbolNPCE
CompanyNeuropace Inc
CEOMr. Joel D. Becker
Websitehttps://www.neuropace.com/
KeyAI